12Indexed trials
drug · Product Intelligence
Lamotrigine
Pipeline Intelligence
Lamotrigine: 12 indexed trials, 7 sponsors; 0 linked Orange Book patents and 8 FDA-linked events where matched.
7Sponsors
0Orange Book patent links
8FDA-linked events
Development evidence
NCT00044278GlaxoSmithKline · epilepsyPHASE2
NCT00088452Children's Hospital Medical Center, Cincinnati · epilepsyPHASE3
NCT00144872GlaxoSmithKline · epilepsyPHASE1
NCT00280059Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · epilepsyPHASE3
NCT00412191GlaxoSmithKline · epilepsyPHASE1
NCT00516139GlaxoSmithKline · epilepsyPHASE3
NCT00579982GlaxoSmithKline · other_psychiatryPHASE3
NCT01376180GlaxoSmithKline · epilepsyCOMPLETED
NCT01733394University of Cincinnati · epilepsyPHASE4
NCT01891890Emory University · epilepsyPHASE3
NCT02256124Erasmus Medical Center · other_neurologyPHASE2, PHASE3
NCT04602221Boehringer Ingelheim · other_neurologyPHASE1
FDA / patent evidence
Orange Book match found; no listed patent relation was retained for this product match.
Regulatory context
FDA_APPROVALLAMOTRIGINE · 2024-09-26
FDA_APPROVALLAMOTRIGINE · 2011-04-08
FDA_APPROVALLAMOTRIGINE · 2009-02-04
FDA_APPROVALLAMOTRIGINE · 2009-01-27
FDA_APPROVALLAMOTRIGINE · 2009-01-27
FDA_APPROVALLAMOTRIGINE · 2009-01-27
FDA_APPROVALLAMOTRIGINE · 2009-01-22
FDA_APPROVALLAMICTAL · 1994-12-27
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.